Auxilium

Press Releases

Keyword Search
 

Below please find a listing of the most recent Auxilium press releases.

DateTitle 
Apr 14, 2014Auxilium and Sobi Announce Encore Presentation of XIAFLEX/Xiapex Data at European Association of Urology Congress
Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These ... 
Printer Friendly Version
Apr 7, 2014Sobi Becomes Market Authorisation Holder For Xiapex in Europe
STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced  that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture patients w... 
Printer Friendly Version
Mar 4, 2014Auxilium Pharmaceuticals, Inc. To Present At The Barclay's Global Healthcare Conference
CHESTERBROOK, Pa., March 4, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET on Tuesday,... 
Printer Friendly Version
Feb 28, 2014Auxilium Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results And Guidance For 2014
FY 2013 Net Revenues of $400.7 Million, a 32% Increase Over 2012 Non-GAAP Net Revenues FY 2013 Non-GAAP EPS Grew 77% to $0.62 2014 Guidance for Net Revenues of $450 - $490 Million CHESTERBROOK, Pa., Feb. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory a... 
Printer Friendly Version
Feb 25, 2014Auxilium Pharmaceuticals, Inc. To Present At The Cowen And Company Annual Healthcare Conference
CHESTERBROOK, Pa., Feb. 25, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Cowen and Company 34th Annual Healthcare Conference to be held March 3-5, 2014 at the Boston Marriott Copley Place Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its produ... 
Printer Friendly Version
Feb 24, 2014Auxilium Pharmaceuticals, Inc. Announces The FDA Acceptance Of Application Requesting Approval Of XIAFLEX® For The Concurrent Treatment Of Multiple Palpable Cords
PDUFA Date Scheduled for October 20, 2014 CHESTERBROOK, Pa., Feb. 24, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's submission of a supplemental Biologics License Application (sBLA) requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of two  Dupuytren's contracture (DC) cords conc... 
Printer Friendly Version
Feb 21, 2014Auxilium Pharmaceuticals, Inc. To Announce Fourth Quarter And Full Year 2013 Results On February 28, 2014
-Company to Host Conference Call That Day at 9 a.m. ET- CHESTERBROOK, Pa., Feb. 21, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the Company will release results for the fourth quarter and full year 2013 on Friday, February 28, 2014 before the opening of the U.S. financial markets. The Company also will conduct a conference call that day at 9 a.m. ET to discuss results and highlights of the f... 
Printer Friendly Version
Feb 19, 2014Auxilium Pharmaceuticals, Inc. To Present At The RBC Capital Markets Healthcare Conference
CHESTERBROOK, Pa., Feb. 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the RBC Capital Markets Healthcare Conference to be held February 25-26, 2014 at the New York Palace Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 1:35 ... 
Printer Friendly Version
Feb 19, 2014Auxilium Pharmaceuticals, Inc. To Ring the NASDAQ Stock Market Opening Bell On February 26, 2014
-Company Marks Milestone of Two New Product Launches- CHESTERBROOK, Pa., Feb. 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on February 26, 2014 to celebrate Auxilium's transformation into a leading men's healthcare company, including two recent launches of new products in men's healthcare, XIAFLEX® (collagenase cl... 
Printer Friendly Version
Feb 5, 2014Auxilium Pharmaceuticals, Inc. To Present At The Leerink Swann Global Healthcare Conference
CHESTERBROOK, Pa., Feb. 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Leerink Swann Global Healthcare Conference to be held February 11-13, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to participate in a discussion about the Company at 10:40 a.m. ET on Wed... 
Printer Friendly Version
Feb 3, 2014Auxilium Pharmaceuticals, Inc. To Present At The BIO CEO & Investor Conference
CHESTERBROOK, Pa., Feb. 3, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the BIO CEO & Investor Conference to be held February 10-11, 2014 at the Waldorf Astoria Hotel in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 9 a.m. ET on M... 
Printer Friendly Version
Jan 21, 2014VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil)
MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that proposes to revise the STENDRA™ (avanafil) prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with... 
Printer Friendly Version
Jan 8, 2014Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the executive management team will participate in the J.P. Morgan 32nd Annual Healthcare Conference to be held January 13-16, 2014 at the Westin St. Francis Hotel in San Francisco. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 4 p.m. PT on W... 
Printer Friendly Version
Jan 8, 2014Auxilium Pharmaceuticals Presents Interim Data on XIAFLEX® for the Retreatment of Recurring Dupuytren's Contracture at the American Association for Hand Surgery 2014 Annual Meeting
Data Show Recurrent Hand Contractures Treated Successfully in Nearly 90 Percent of Patients; Retreatment Shown to be Well-Tolerated CHESTERBROOK, Pa., Jan. 8, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that interim data from its Phase 4 retreatment study (AUX-CC-862) evaluating XIAFLEX® (collagenase clostridium histolyticum or CCH) in adult patients with Dupuytren's contracture (DC) and a rec... 
Printer Friendly Version
Dec 20, 2013Auxilium Pharmaceuticals, Inc. Submits Application To The FDA Requesting Approval Of XIAFLEX® For Concurrent Treatment Of Multiple Palpable Cords
sBLA Submitted for Dupuytren's Contracture, a Progressive Hand Disease that Can Present with Multiple Collagen "Cords" That Limit Movement and Function CHESTERBROOK, Pa., Dec. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) requesting approval of XIAFLEX (collagenase clostridium hi... 
Printer Friendly Version
Dec 13, 2013Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
CHESTERBROOK, Pa., Dec. 13, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the first patient was dosed in its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome (FSS). FSS can be a prolonged, painful condition of the shoulder in which increased capsular collagen thickening and subsequen... 
Printer Friendly Version
Dec 6, 2013Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX® for the Treatment of Peyronie's Disease
XIAFLEX is First and Only FDA-Approved Treatment Proven Effective for Peyronie's Disease Company to Host Conference Call Today at 1:30 p.m. ET CHESTERBROOK, Pa., Dec. 6, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved XIAFLEX® (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease ... 
Printer Friendly Version
Dec 5, 2013Auxilium Pharmaceuticals, Inc. To Present At The Oppenheimer Conference
CHESTERBROOK, Pa., Dec. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the Oppenheimer 24th Annual Conference to be held December 10-11, 2013 at the Crown Plaza in New York. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30 a.m. ET on Wednesday, December 11, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10... 
Printer Friendly Version
Dec 4, 2013Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
CHESTERBROOK, Pa., Dec. 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") announced today that the United States District Court for the District of Delaware ("Court") granted Upsher-Smith Laboratories, Inc.'s ("USL") motion for summary judgment with respect to its attempts to bring a testosterone gel product to market via its 505(b)(2) NDA using Auxilium's Testim® product as its reference listed drug. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881L... 
Printer Friendly Version
Nov 25, 2013Auxilium Pharmaceuticals Presented New Analyses of XIAFLEX® Peyronie's Disease Data at SMSNA Scientific Meeting
- Six abstracts presented throughout meeting - CHESTERBROOK, Pa., Nov. 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, has announced that new and updated data were presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disea... 
Printer Friendly Version
Nov 20, 2013Auxilium Pharmaceuticals, Inc. to Present Data on XIAFLEX® at the Fall Scientific Meeting of the Sexual Medicine Society of North America
-Multiple Studies of XIAFLEX for the Potential Treatment of Peyronie's Disease to be Presented- CHESTERBROOK, Pa., Nov. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) for the potential treatment of Peyronie's disease, will be presented at the upcoming 19th Annual Fall Scientific Meeting of the Sexual Medicine ... 
Printer Friendly Version
Nov 18, 2013Auxilium Announces Results Of The XIAFLEX® In Dupuytren's MULTICORD Contracture Trial
- Expects to submit supplemental Biologics License Application to the FDA in the first quarter of 2014 that supports potential labeling expansion for concurrent treatment of multiple palpable cords- CHESTERBROOK, Pa., Nov. 18, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced the results of the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) study, a... 
Printer Friendly Version
Nov 6, 2013Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
- 3Q13 Total Net Revenues Increased by 52% vs. 3Q12 to $108.1 MM - CHESTERBROOK, Pa., Nov. 6, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the quarter ending September 30, 2013.  The Company also highlighted select commercial, regulatory and clinical development progress in the third quarter of 2013 and updated guidance for full year 2013. (Logo: http://photos.prnewswire.c... 
Printer Friendly Version
Oct 24, 2013Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6, 2013
CHESTERBROOK, Pa., Oct. 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, will release results for the third quarter 2013 on Wednesday, November 6, 2013. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the third quarter.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "... 
Printer Friendly Version
Oct 23, 2013Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum
- Topline Results are Expected in the First Quarter of 2015 - CHESTERBROOK, Pa., Oct. 23, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known as cellulite.  As previously reported, Phase 1b open label dose-ranging study resul... 
Printer Friendly Version
Oct 11, 2013Auxilium Pharmaceuticals, Inc. Announces License Agreement For The Marketing Rights To STENDRA™ In The United States And Canada
- STENDRA Broadens Auxilium's Presence in Men's Health Care With a Projected 2013 Launch into the Multi-Billion Dollar Erectile Dysfunction Market - CHESTERBROOK, Pa., Oct. 11, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. (Nasdaq: VVUS) providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.  The partie... 
Printer Friendly Version
Oct 7, 2013Auxilium Pharmaceuticals, Inc. Presented Data At The ASSH Annual Meeting About XIAFLEX® For The Treatment Of Dupuytren's Contracture
-42 Percent of Joints Previously Treated Successfully with XIAFLEX Exhibited Disease Recurrence at Year 4- -Three-Year Post-Approval Safety Reports After Approximately 49,000 Injections is Consistent with Safety Profile from Clinical Studies- CHESTERBROOK, Pa., Oct. 7, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced results from Year 4 of the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of S... 
Printer Friendly Version
Oct 3, 2013Auxilium Pharmaceuticals, Inc. to Present Data on XIAFLEX® in the Treatment of Dupuytren's Contracture at the American Society for Surgery of the Hand (ASSH) Annual Meeting
- Four-Year Data from CORDLESS Recurrence Study and Three-Year Safety Data to be Presented as Clinical Papers - CHESTERBROOK, Pa., Oct. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data from multiple trials evaluating the use of XIAFLEX ("collagenase clostridium histolyticum" or "CCH") in adult patients with Dupuytren's contracture with a palpable cord will be presented at the upcoming 68th Annual Meeting ... 
Printer Friendly Version
Sep 20, 2013Auxilium Pharmaceuticals, Inc. Raises $50 Million In Additional Financing
CHESTERBROOK, Pa., Sept. 20, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced it entered into an Incremental Assumption Agreement ("Incremental Agreement") with Morgan Stanley Senior Funding, Inc. ("MSSF") under its existing Credit Agreement with MSSF.  Under the Incremental Agreement, the Company raised an additional $50,000,000 from a syndicate of lenders, and this additional amount is on terms consistent with its existi... 
Printer Friendly Version
Sep 5, 2013Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
CHESTERBROOK, Pa., Sept. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Stifel Nicolaus Healthcare Conference to be held September 11-12, 2013 at the Four Seasons Hotel in Boston.  Mr. Jim Fickenscher, Chief Financial Officer, is scheduled to present an overview of the Company and its product pipeline at 8:00 a.m. ET on Thursday, September 12, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10... 
Printer Friendly Version
Sep 3, 2013Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
CHESTERBROOK, Pa., Sept. 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Morgan Stanley Global Healthcare Conference to be held September 9-11, 2013 at the Grand Hyatt Hotel in New York.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:35 a.m. ET on Monday, September 9, 2013.   (Logo: http://photos.prnewswire.com/prn... 
Printer Friendly Version
Aug 28, 2013Auxilium Receives Notification of XIAFLEX® PDUFA Extension
CHESTERBROOK, Pa., Aug. 28, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration ("FDA") has notified the Company that it is extending the Prescription Drug User Fee Act ("PDUFA") goal date for the Company's supplemental biologics license application ("sBLA") for XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie's disease ("PD") from September 6, 2013 to De... 
Printer Friendly Version
Aug 8, 2013Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
CHESTERBROOK, Pa., Aug. 8, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Canaccord Genuity Growth Conference to be held August 14-15, 2013 at the Intercontinental Boston Hotel.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 3:30 p.m. ET on Thursday, August 15, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/M... 
Printer Friendly Version
Aug 1, 2013Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
- 2Q13 Total Net Revenues Increased by 29% vs. 2Q12 to $100.5 MM - - 2013 Guidance Updated- CHESTERBROOK, Pa., Aug. 1, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the quarter ending on June 30, 2013.  The Company also highlighted select commercial, regulatory and clinical development progress in the second quarter of 2013 and has updated its previously announced financial guidance for 201... 
Printer Friendly Version
Jul 24, 2013Auxilium Pharmaceuticals to Announce Second Quarter 2013 Results and Conduct Conference Call on Thursday, August 1, 2013
CHESTERBROOK, Pa., July 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the second quarter 2013 on Thursday, August 1, 2013. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the second quarter.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab... 
Printer Friendly Version
Jul 16, 2013Auxilium Pharmaceuticals, Inc. And Swedish Orphan Biovitrum AB (publ) Enter A Collaboration Agreement For XIAPEX® In 71 Eurasian And African Countries
-Sobi Obtains Exclusive Rights for One Commercial and One Development Indication for XIAPEX- -In Addition to Royalties, Auxilium to Receive up to $40MM in Potential Aggregate Sales Milestones- CHESTERBROOK, Pa., and STOCKHOLM, July 16, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (STO: SOBI) announced today that they have entered into a long-term collaboration for the development, supply and commercialization of XIAPEX (collage... 
Printer Friendly Version
Jul 3, 2013Auxilium Pharmaceuticals, Inc. to Present at the 8th Annual JMP Securities Healthcare Conference
CHESTERBROOK, Pa., July 3, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the 8th Annual JMP Securities Healthcare Conference to be held July 9-10, 2013 at the St. Regis hotel in New York City.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 9:30 a.m. ET on Wednesday, July 10, 2013.   (Logo:  http://photos.prnewswire.com/prn... 
Printer Friendly Version
Jun 11, 2013Men's Health Network And Auxilium Pharmaceuticals, Inc. Mark Men's Health Month With "Ask About The Curve™" Collaboration To Encourage Greater Understanding Of Peyronie's Disease
National Survey Reveals Gaps in Perceptions and Realities of Living with Peyronie's Disease, as Experienced by Both Men and Their Partners WASHINGTON, and CHESTERBROOK, Pa., June 11, 2013 /PRNewswire/ -- Men's Health Network ("MHN") and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, have announced the launch of a new health awareness program called "Ask About the Curve" to provide information about Peyronie's disease (PD) and to help empower men to hav... 
Printer Friendly Version
Jun 7, 2013Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
CHESTERBROOK, Pa., June 7, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Goldman Sachs 34th Annual Global Healthcare Conference to be held June 11-13, 2013 at the Terranea Hotel in Rancho Palos Verdes, CA.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:40 a.m. PT (1:40 p.m. ET) on Thursday, June 13, 2013.   (Logo: h... 
Printer Friendly Version
May 31, 2013Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
CHESTERBROOK, Pa., May 31, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Jefferies 2013 Healthcare Conference to be held June 3-6, 2013 at the Grand Hyatt in New York City.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 4:00 p.m. ET on Wednesday, June 5, 2013.   (Logo:  http://photos.prnewswire.com/prnh/20101202/MM1088... 
Printer Friendly Version
May 24, 2013Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
CHESTERBROOK, Pa., May 24, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Deutsche Bank Health Care Conference to be held May 29-30 at the Westin Boston Waterfront Hotel.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 12:00 p.m. ET on Wednesday, May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LO... 
Printer Friendly Version
May 15, 2013Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
CHESTERBROOK, Pa., May 15, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the UBS Global Health Care Conference to be held May 20-22 at the Sheraton New York Hotel.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 3:00 p.m. ET on Wednesday, May 21, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The... 
Printer Friendly Version
May 10, 2013Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
CHESTERBROOK, Pa., May 10, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Bank of America Merrill Lynch 2013 Health Care Conference to be held May 14-16 at the Encore at the Wynn Las Vegas.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 3:00 p.m. PT (6:00 pm ET) on Wednesday, May 15, 2013.   (Logo: http://photos.prnewsw... 
Printer Friendly Version
Apr 29, 2013Auxilium Pharmaceuticals, Inc, Announces First Quarter 2013 Financial Results
- 1Q13 Net Revenues Decreased by 10% from 1Q12 to $66.2 MM - - Acquisition of Actient Holdings LLC to Create a Leading Urology Franchise with a Diversified Product Portfolio and Strong Growth Profile - CHESTERBROOK, Pa., April 29, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the first quarter ending on March 31, 2013.  The Company also highlighted important recent commercial, regulatory an... 
Printer Friendly Version
Apr 29, 2013Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
-Transaction Expected to be Immediately Accretive to Adjusted Non-GAAP Net Income- CHESTERBROOK, Pa. and LAKE FOREST, Ill., April 29, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that it has completed the acquisition of  Actient Holdings LLC ("Actient"), a private urology specialty therapeutics company, for $585 million in upfront cash plus certain contingent consideration and warrants to purchase Auxilium common ... 
Printer Friendly Version
Apr 25, 2013Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
CHESTERBROOK, Pa., April 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2013 on Monday, April 29, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the first quarter.  The presentation slides to be used during the call will be available on the "For Investors" section of the Com... 
Printer Friendly Version